FDA New Drug Application In The Works For This Innovator In ADHD Drug Delivery
- 11 days ago
Shane Schaffer, Chairman & CEO, and Peter J. Werth, Board Member of Cingulate, were recently guests on Benzinga's All Access.
Cingulate is a biotechnology company that is developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, allowing for relief of the pill burden many people with chronic conditions suffer.
The company is preparing an application for new drug approval for its lead candidate, CTx-1301.
Cingulate is a biotechnology company that is developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, allowing for relief of the pill burden many people with chronic conditions suffer.
The company is preparing an application for new drug approval for its lead candidate, CTx-1301.